1AI 12.5% 0.7¢ algorae pharmaceuticals limited

Recent events, page-78

  1. 2,978 Posts.
    lightbulb Created with Sketch. 69
    the same reason that selective vitamins are no substitute for whole-plant-based vitamins a single reductionist treatment always but always lacks the complete package for a complete "round-trip" treatment

    neurotrophic factory of NTCell is not a single target approach

    "CuATSM is a small synthetic molecule that contains copper. ..developed in Japan as an imaging agent for hypoxic tissues, based on finding that CuATSM selectively delivers copper to hypoxic tissues, but not normal tissues. In 2005....began discussing the potential of CuATSM to treat neurodegenerative diseases. Subsequently, they showed that CuATSM selectively releases copper in cells with damaged mitochondrial electron transport chains, which are characteristic of many neurodegenerative diseases, including ALS/MND, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease. They also showed that CuATSM eliminates peroxynitrite, a chemical that inhibits components of the mitochondrial electron transport chain. CMD licensed commercial rights to CuATSM for treatment of neurodegenerative diseases from the University of Melbourne."

    imho, there you have the frame work of the design, it is singular, a reductionist approach

    https://colmeddev.com/trials/


 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
(20min delay)
Last
0.7¢
Change
-0.001(12.5%)
Mkt cap ! $11.81M
Open High Low Value Volume
0.7¢ 0.8¢ 0.7¢ $6.741K 948.6K

Buyers (Bids)

No. Vol. Price($)
9 9337674 0.7¢
 

Sellers (Offers)

Price($) Vol. No.
0.8¢ 1913304 15
View Market Depth
Last trade - 13.30pm 11/09/2024 (20 minute delay) ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.